Find out more about our clinical trials: Read More

Learn More About Our Innovative Biotechnology

Press Releases, Publications, & Videos

Videos
Featured
Oncology Tube Profiles Acceleration of Dosing in AVM NHL Clinical Trial

Oncology Tube highlights the FDA approval of accelerated dosing in AVM Biotechnology’s adaptive design expansion cohort clinical trial treating Non-Hodgkin’s Lymphoma/Leukemia.

Press Releases
A71D6692-5CFE-4689-B857-C80775B0E4E8

FDA Approves Accelerated Dosing in NHL/Leukemia Clinical Trial

Press Releases
A71D6692-5CFE-4689-B857-C80775B0E4E8

Full Enrollment of First Cohort of Relapsed/Refractory Non-Hodgkin’s Lymphoma Patients dosed with AVM0703

AVM Biotech
Videos
Group 3

Theresa Deisher Speaks at ESWI Influenza Conference

Publications
A71D6692-5CFE-4689-B857-C80775B0E4E8

AVM Biotechnology – The Platform Therapy for Immune Modulation

Publications
A71D6692-5CFE-4689-B857-C80775B0E4E8

Pharma’s Almanac Features AVM0703

Press Releases
A71D6692-5CFE-4689-B857-C80775B0E4E8

AVM Biotechnology CEO/CSO Selected to Speak at ESWI Conference in Novel and Outstanding Discoveries Track

AVM Biotech
Videos
Group 3

What is AVM0703? Find Out!

Press Releases
A71D6692-5CFE-4689-B857-C80775B0E4E8

President Receives Dexamethasone Treatment

Press Releases
A71D6692-5CFE-4689-B857-C80775B0E4E8

AVM Receives FDA Permission for Clinical Trials in COVID-19/ARDS

Press Releases
A71D6692-5CFE-4689-B857-C80775B0E4E8

AVM Expands Executive Team, Appoints Janet R. Rea COO

AVM Biotech
Videos
Group 3

Amplifying Scientific Innovation Podcast

Press Releases
A71D6692-5CFE-4689-B857-C80775B0E4E8

AVM’s Dexamethasone Formulation Has Potential For Greater Impact Than Oxford’s

AVM Biotech
Videos
Group 3

Oxford/AVM’s potential COVID-19 Treatment Featured on KOMO News

Press Releases
A71D6692-5CFE-4689-B857-C80775B0E4E8

AVM Awarded SBIR Grant From National Cancer Institute

Press Releases
A71D6692-5CFE-4689-B857-C80775B0E4E8

FDA Approves AVM0703 Clinical Trials in R/R Non-Hodgkins Lymphoma

AVM Biotech
Videos
Group 3

Cavendish Global 2020

Publications
A71D6692-5CFE-4689-B857-C80775B0E4E8

AVM0703, a New Treatment Option for Lymphoma Patients

Mobilizing the Supercharged Immune Armies Within